Peptide library › Metabolic & weight
Glucagon
Also known as GlucaGen, Gvoke, Baqsimi (nasal)
Emergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.
What people use it for
- Severe low blood sugar (hypoglycaemia) in diabetes
- Relaxing the stomach and gut for X-ray or MRI imaging
What Glucagon does in the body
A 29-amino-acid hormone made by the pancreas that works opposite to insulin: it tells the liver to release stored sugar into the blood. It only works if the liver has sugar stores.
Strength of evidence
Strong: long-established emergency treatment.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and vomiting
- Headache
- Temporary fast heart rate
Who should avoid it or take extra care
- Phaeochromocytoma (a rare adrenal tumour)
- Insulinoma (a rare insulin-making tumour)
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved for decades. Ready-to-use injections (Gvoke) and a nasal powder (Baqsimi) are newer options.
How it's taken
Route: Injection under the skin or into a muscle, or a nasal powder
How long it lasts (half-life): About 8 to 18 minutes
Storage
At room temperature in its kit; check the expiry date regularly.
Latest research & news
- Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature
Research · Review · PubMed · Am J Dermatopathol · 21 Nov 2026 - The GLP-1 receptor agonist semaglutide reduces alcohol consumption and anxiety-like behaviors during withdrawal in Marchigian Sardinian alcohol-preferring rats
Research · Lab or animal study · PubMed · Neuropharmacology · 21 Nov 2026 - A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Clinical trial · Active not recruiting · Updated · ClinicalTrials.gov · 20 Nov 2026 - A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Clinical trial · Completed · Phase 2 · Updated · ClinicalTrials.gov · 20 Nov 2026 - A Study of IBI3042 in Healthy Adult Participants
Clinical trial · Recruiting · Phase 1 · Updated · ClinicalTrials.gov · 20 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Glucagon privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Glucagon in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- AmycretinExperimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- LixisenatideOnce-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
- PemvidutideExperimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- Insulin analogsLab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
- DasiglucagonStable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.